Skip to main content
SpringerLink
Log in

Eingriffe unter NOAK

Was ist möglich?

Procedures on patients receiving NOACs

What’s possible?

  • Leitthema
  • Published:
Medizinische Klinik - Intensivmedizin und Notfallmedizin Aims and scope Submit manuscript

    We’re sorry, something doesn't seem to be working properly.

    Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Zusammenfassung

Nicht-Vitamin-K-antagonistische orale Antikoagulanzien (NOAK) werden in den letzten Jahren vermehrt bei Patienten mit nichtvalvulärem Vorhofflimmern, venöser Thrombose und Lungenembolie eingesetzt. Allerdings sind die Erfahrungen mit diesen neuen Substanzen im Rahmen des periinterventionellen, perioperativen und intensivmedizinischen Managements noch sehr eingeschränkt. Aufgrund der fehlenden Evidenz basieren die aktuellen Empfehlungen zum Umgang mit Patienten unter NOAK in diesem Rahmen auf Analysen der Pharmakokinetik in Kombination mit patientenspezifischen Charakteristiken, dem jeweiligen Blutungsrisiko des geplanten Eingriffs und der Dringlichkeit der Prozedur. Dieser Review fasst die Evidenz und Empfehlungen zum optimalen periinterventionellen/perioperativen/intensivmedizinischen antithrombotischen Management bei Patienten unter NOAK-Therapie zusammen.

Abstract

Non-vitamin K antagonist oral anticoagulants (NOACs) are increasingly used in patients with deep vein thrombosis (DVT), pulmonary embolism (PE) and atrial fibrillation (AF). However, there is insufficient data concerning the periinterventional, perioperative, and intensive care management of patients on NOACs. Therefore, the recommendations regarding this management rely on pharmacokinetics of the particular NOAC in combination with the individual patient’s characteristics, bleeding risk of the planned intervention/surgery, and urgency of the procedure. This review summarizes evidence and recommendations regarding the optimal periinterventional/perioperative antithrombotic management of patients on NOACs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361:1139–1151

    Article  CAS  PubMed  Google Scholar 

  2. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365:883–891

    Article  CAS  PubMed  Google Scholar 

  3. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365:981–992

    Article  CAS  PubMed  Google Scholar 

  4. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, Spinar J, Ruzyllo W, Ruda M, Koretsune Y, Betcher J, Shi M, Grip LT, Patel SP, Patel I, Hanyok JJ, Mercuri M, Antman EM (2013) Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 369:2093–2104

    Article  CAS  PubMed  Google Scholar 

  5. Caldeira D, Barra M, Pinto FJ, Ferreira JJ, Costa J (2015) Intracranial hemorrhage risk with the new oral anticoagulants: a systematic review and meta-analysis. J Neurol 262:516–522

    Article  CAS  PubMed  Google Scholar 

  6. Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, Baanstra D, Schnee J, Goldhaber SZ (2009) Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 361:2342–2352

    Article  CAS  PubMed  Google Scholar 

  7. Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, Lensing AW, Misselwitz F, Prins MH, Raskob GE, Segers A, Verhamme P, Wells P, Agnelli G, Bounameaux H, Cohen A, Davidson BL, Piovella F, Schellong S (2010) Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 363:2499–2510

    Article  CAS  PubMed  Google Scholar 

  8. Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Masiukiewicz U, Pak R, Thompson J, Raskob GE, Weitz JI (2013) Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 369:799–808

    Article  CAS  PubMed  Google Scholar 

  9. Buller HR, Decousus H, Grosso MA, Mercuri M, Middeldorp S, Prins MH, Raskob GE, Schellong SM, Schwocho L, Segers A, Shi M, Verhamme P, Wells P (2013) Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 369:1406–1415

    Article  PubMed  Google Scholar 

  10. Sardar P, Chatterjee S, Lavie CJ, Giri JS, Ghosh J, Mukherjee D, Lip GY (2015) Risk of major bleeding in different indications for new oral anticoagulants: insights from a meta-analysis of approved dosages from 50 randomized trials. Int J Cardiol 179:279–287

    Article  PubMed  Google Scholar 

  11. Lauffenburger JC, Farley JF, Gehi AK, Rhoney DH, Brookhart MA, Fang G (2015) Factors driving anticoagulant selection in patients with atrial fibrillation in the United States. Am J Cardiol 115:1095–1101

    Article  PubMed  PubMed Central  Google Scholar 

  12. Schwabe U, Paffrath D (2015) Arzneiverordnungs-Report 2015: Aktuelle Zahlen, Kosten, Trends und Kommentare. Springer, Berlin

    Book  Google Scholar 

  13. Healey JS, Eikelboom J, Douketis J, Wallentin L, Oldgren J, Yang S, Themeles E, Heidbuchel H, Avezum A, Reilly P, Connolly SJ, Yusuf S, Ezekowitz M (2012) Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial. Circulation 126:343–348

    Article  CAS  PubMed  Google Scholar 

  14. Heidbuchel H, Verhamme P, Alings M, Antz M, Diener HC, Hacke W, Oldgren J, Sinnaeve P, Camm AJ, Kirchhof P (2015) Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 17:1467–1507

    Article  PubMed  Google Scholar 

  15. Shoeb M, Fang MC (2013) Assessing bleeding risk in patients taking anticoagulants. J Thromb Thrombolysis 35:312–319

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Reilly PA, Lehr T, Haertter S, Connolly SJ, Yusuf S, Eikelboom JW, Ezekowitz MD, Nehmiz G, Wang S, Wallentin L (2014) The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). J Am Coll Cardiol 63:321–328

    Article  CAS  PubMed  Google Scholar 

  17. Olesen JB, Lip GY, Kamper AL, Hommel K, Kober L, Lane DA, Lindhardsen J, Gislason GH, Torp-Pedersen C (2012) Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med 367:625–635

    Article  CAS  PubMed  Google Scholar 

  18. Weinstein JR, Anderson S (2010) The aging kidney: physiological changes. Adv Chronic Kidney Dis 17:302–307

    Article  PubMed  PubMed Central  Google Scholar 

  19. Ferguson JJ, Califf RM, Antman EM, Cohen M, Grines CL, Goodman S, Kereiakes DJ, Langer A, Mahaffey KW, Nessel CC, Armstrong PW, Avezum A, Aylward P, Becker RC, Biasucci L, Borzak S, Col J, Frey MJ, Fry E, Gulba DC, Guneri S, Gurfinkel E, Harrington R, Hochman JS, Kleiman NS, Leon MB, Lopez-Sendon JL, Pepine CJ, Ruzyllo W, Steinhubl SR, Teirstein PS, Toro-Figueroa L, White H (2004) Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA 292:45–54

    CAS  PubMed  Google Scholar 

  20. Cappato R, Calkins H, Chen SA, Davies W, Iesaka Y, Kalman J, Kim YH, Klein G, Natale A, Packer D, Skanes A, Ambrogi F, Biganzoli E (2010) Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circ Arrhythm Electrophysiol 3:32–38

    Article  PubMed  Google Scholar 

  21. Sticherling C, Marin F, Birnie D, Boriani G, Calkins H, Dan GA, Gulizia M, Halvorsen S, Hindricks G, Kuck KH, Moya A, Potpara T, Roldan V, Tilz R, Lip GY (2015) Antithrombotic management in patients undergoing electrophysiological procedures: a European Heart Rhythm Association (EHRA) position document endorsed by the ESC Working Group Thrombosis, Heart Rhythm Society (HRS), and Asia Pacific Heart Rhythm Society (APHRS). Europace 17:1197–1214

    Article  PubMed  Google Scholar 

  22. Di Biase L, Burkhardt JD, Santangeli P, Mohanty P, Sanchez JE, Horton R, Gallinghouse GJ, Themistoclakis S, Rossillo A, Lakkireddy D, Reddy M, Hao S, Hongo R, Beheiry S, Zagrodzky J, Rong B, Mohanty S, Elayi CS, Forleo G, Pelargonio G, Narducci ML, Dello Russo A, Casella M, Fassini G, Tondo C, Schweikert RA, Natale A (2014) Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the Role of Coumadin in Preventing Thromboembolism in Atrial Fibrillation (AF) Patients Undergoing Catheter Ablation (COMPARE) randomized trial. Circulation 129:2638–2644

    Article  PubMed  Google Scholar 

  23. Cappato R, Marchlinski FE, Hohnloser SH, Naccarelli GV, Xiang J, Wilber DJ, Ma CS, Hess S, Wells DS, Juang G, Vijgen J, Hugl BJ, Balasubramaniam R, De Chillou C, Davies DW, Fields LE, Natale A (2015) Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation. Eur Heart J 36:1805–1811

    Article  PubMed  PubMed Central  Google Scholar 

  24. Hohnloser SH, Camm AJ (2013) Safety and efficacy of dabigatran etexilate during catheter ablation of atrial fibrillation: a meta-analysis of the literature. Europace 15:1407–1411

    Article  PubMed  Google Scholar 

  25. Aryal MR, Ukaigwe A, Pandit A, Karmacharya P, Pradhan R, Mainali NR, Pathak R, Jalota L, Bhandari Y, Donato A (2014) Meta-analysis of efficacy and safety of rivaroxaban compared with warfarin or dabigatran in patients undergoing catheter ablation for atrial fibrillation. Am J Cardiol 114:577–582

    Article  CAS  PubMed  Google Scholar 

  26. Blandino A, Bianchi F, Biondi-Zoccai G, Grossi S, Conte MR, Rametta F, Gaita F (2016) Apixaban for periprocedural anticoagulation during catheter ablation of atrial fibrillation: a systematic review and meta-analysis of 1691 patients. J Interv Card Electrophysiol 46(3):225–236. doi:10.1007/s10840-016-0141-6

    Article  PubMed  Google Scholar 

  27. Birnie DH, Healey JS, Wells GA, Verma A, Tang AS, Krahn AD, Simpson CS, Ayala-Paredes F, Coutu B, Leiria TL, Essebag V (2013) Pacemaker or defibrillator surgery without interruption of anticoagulation. N Engl J Med 368:2084–2093

    Article  CAS  PubMed  Google Scholar 

  28. Kosiuk J, Koutalas E, Doering M, Sommer P, Rolf S, Breithardt OA, Nedios S, Dinov B, Hindricks G, Richter S, Bollmann A (2014) Treatment with novel oral anticoagulants in a real-world cohort of patients undergoing cardiac rhythm device implantations. Europace 16:1028–1032

    Article  PubMed  Google Scholar 

  29. van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, Clemens A (2010) Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 103:1116–1127

    Article  PubMed  Google Scholar 

  30. Pfeilschifter W, Abruscato M, Hovelmann S, Baas H (2013) Thrombolysis in a stroke patient on dabigatran anticoagulation: case report and synopsis of published cases. Case Rep Neurol 5:56–61

    Article  PubMed  PubMed Central  Google Scholar 

  31. Huisman MV, Lip GY, Diener HC, Brueckmann M, van Ryn J, Clemens A (2012) Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice. Thromb Haemost 107:838–847

    Article  CAS  PubMed  Google Scholar 

  32. Douxfils J, Mullier F, Loosen C, Chatelain C, Chatelain B, Dogne JM (2012) Assessment of the impact of rivaroxaban on coagulation assays: laboratory recommendations for the monitoring of rivaroxaban and review of the literature. Thromb Res 130:956–966

    Article  CAS  PubMed  Google Scholar 

  33. Beyer-Westendorf J, Forster K, Pannach S, Ebertz F, Gelbricht V, Thieme C, Michalski F, Kohler C, Werth S, Sahin K, Tittl L, Hansel U, Weiss N (2014) Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry. Blood 124:955–962

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Pollack CV Jr., Reilly PA, Eikelboom J, Glund S, Verhamme P, Bernstein RA, Dubiel R, Huisman MV, Hylek EM, Kamphuisen PW, Kreuzer J, Levy JH, Sellke FW, Stangier J, Steiner T, Wang B, Kam CW, Weitz JI (2015) Idarucizumab for dabigatran reversal. N Engl J Med 373:511–520

    Article  CAS  PubMed  Google Scholar 

  35. Rene AG, Genereux P, Ezekowitz M, Kirtane AJ, Xu K, Mehran R, Brener SJ, Stone GW (2014) Impact of atrial fibrillation in patients with ST-elevation myocardial infarction treated with percutaneous coronary intervention (from the HORIZONS-AMI [Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction] trial). Am J Cardiol 113:236–242

    Article  PubMed  Google Scholar 

  36. Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, Filippatos G, Hamm C, Head SJ, Juni P, Kappetein AP, Kastrati A, Knuuti J, Landmesser U, Laufer G, Neumann FJ, Richter DJ, Schauerte P, Sousa Uva M, Stefanini GG, Taggart DP, Torracca L, Valgimigli M, Wijns W, Witkowski A (2014) 2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 35:2541–2619

    Article  PubMed  Google Scholar 

  37. Lip GY, Windecker S, Huber K, Kirchhof P, Marin F, Ten Berg JM, Haeusler KG, Boriani G, Capodanno D, Gilard M, Zeymer U, Lane D, Storey RF, Bueno H, Collet JP, Fauchier L, Halvorsen S, Lettino M, Morais J, Mueller C, Potpara TS, Rasmussen LH, Rubboli A, Tamargo J, Valgimigli M, Zamorano JL (2014) Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). Eur Heart J 35:3155–3179

    Article  CAS  PubMed  Google Scholar 

  38. Mar PL, Familtsev D, Ezekowitz MD, Lakkireddy D, Gopinathannair R (2016) Periprocedural management of anticoagulation in patients taking novel oral anticoagulants: review of the literature and recommendations for specific populations and procedures. Int J Cardiol 202:578–585

    Article  PubMed  Google Scholar 

  39. Hacke W (2015) Interventional thrombectomy for major stroke – a step in the right direction. N Engl J Med 372:76–77

    Article  PubMed  Google Scholar 

Download references

Förderung

Das Entstehen dieser Arbeit wurde durch die Forschungskommission der Heinrich-Heine-Universität Düsseldorf (A.P.: No. 16-2014; P.H.: 30-2014) finanziell unterstützt.

Author information

Authors and Affiliations

  1. Klinik für Kardiologie, Pneumologie und Angiologie, Universitätsklinikum der Heinrich-Heine-Universität Düsseldorf, Moorenstraße 5, 40225, Düsseldorf, Deutschland

    A. Polzin, M. Kelm & P. Horn

Authors
  1. A. Polzin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Kelm
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. P. Horn
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. Polzin.

Ethics declarations

Interessenkonflikt

A. Polzin, M. Kelm und P. Horn geben an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

Additional information

Redaktion

M. Buerke, Siegen

H.M. Hoffmeister, Solingen

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Polzin, A., Kelm, M. & Horn, P. Eingriffe unter NOAK. Med Klin Intensivmed Notfmed 112, 117–124 (2017). https://doi.org/10.1007/s00063-016-0239-8

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00063-016-0239-8

Schlüsselwörter

Keywords

Search

Navigation